- 1、本文档共5页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
三阴性乳腺癌
Prognostic factors for survival in metastatic breast cancer by hormone receptor status
通过激素受体状态判断转移性乳腺癌患者生存预后因素
Abstract
Hormone receptor (HR) status is an important prognostic factor for patients with metastatic breast cancer (MBC) and is also correlated with other prognostic factors, such as initial lymph node status, HER2-Neu status and age. The prognostic value of these other factors, however, is unknown when stratified by HR positive versus HR negative patients. The aim of this study was to evaluate prognostic factors for MBC survival in relation to HR status. Dutch women diagnosed with breast cancer in 2003–2006 treated with curative intent who developed MBC within 5?years of follow-up were selected from the Netherlands cancer registry (N?=?2,001). Independent prognostic factors for survival after metastatic occurrence were determined by multivariable Cox survival analyses stratified by HR status. Interactions between HR status and prognostic factors were determined. Median survival for MBC patients with HR negative (HR?) tumours was 8?months, compared to 19?months for HR positive (HR+) patients. The prognostic value of lymph node status, HER2-Neu status, adjuvant endocrine treatment and first-line palliative chemotherapy was dependent on HR status. Initial lymph node status was independently associated with survival in HR? patients, but not in HR+?patients. HER2-Neu positive status was associated with better survival in both HR+ and HR? patients, although the association was stronger in HR? patients. Similarly, patients treated with first-line palliative chemotherapy fared better, especially HR? patients. HR+ patients had worse survival if they had received adjuvant endocrine treatment. This study shows that the prognostic value of various factors depends on HR status in MBC. This information may help physicians to determine individual prognostic profiles and therapeutic strategies for MBC patients.
对有转移的乳腺癌患者来说,激素受体状态是一个很重要的预后因素,并且和其它的预后因素相关;例如最初的淋巴结状态、HER2和
您可能关注的文档
最近下载
- 征信报告模板-带水印-通用.docx VIP
- 女儿墙维修工程施工方案(3篇).docx VIP
- 找准下一个买卖点.docx VIP
- 2026届高一物理必修一同步1.4 速度变化快慢的描述——加速度(解析版).docx VIP
- UniStrong合众思壮eSurvey2.0软件使用说明书.pdf VIP
- 中国宏桥首次覆盖报告:高景气与一体化与高分红,电解铝龙头静待价值重估.docx VIP
- 中国宏桥-市场前景及投资研究报告:高景气+一体化+高分红,电解铝龙头,价值重估.pdf VIP
- 少女漫画·女作家·日本人-中外文学作品丛书.docx VIP
- 人教版四年级数学上册期末测试卷核心考点.pdf VIP
- 爆破工程技术人员取证培训初级D设计题真题参考答案.pdf VIP
文档评论(0)